Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products … Read more
Hansoh Pharmaceutical Group Company Limited (HNSPF) - Net Assets
Latest net assets as of June 2025: $31.10 Billion USD
Based on the latest financial reports, Hansoh Pharmaceutical Group Company Limited (HNSPF) has net assets worth $31.10 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($35.07 Billion) and total liabilities ($3.97 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $31.10 Billion |
| % of Total Assets | 88.67% |
| Annual Growth Rate | 12.55% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.03 |
Hansoh Pharmaceutical Group Company Limited - Net Assets Trend (2020–2024)
This chart illustrates how Hansoh Pharmaceutical Group Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hansoh Pharmaceutical Group Company Limited (2020–2024)
The table below shows the annual net assets of Hansoh Pharmaceutical Group Company Limited from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $28.68 Billion | +11.18% |
| 2023-12-31 | $25.79 Billion | +13.90% |
| 2022-12-31 | $22.65 Billion | +13.07% |
| 2021-12-31 | $20.03 Billion | +12.05% |
| 2020-12-31 | $17.88 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hansoh Pharmaceutical Group Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1301126100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $13.01 Billion | 45.37% |
| Other Components | $15.67 Billion | 54.63% |
| Total Equity | $28.68 Billion | 100.00% |
Hansoh Pharmaceutical Group Company Limited Competitors by Market Cap
The table below lists competitors of Hansoh Pharmaceutical Group Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taiwan Business Bank
TW:2834
|
$3.25 Billion |
|
Itissalat Al-Maghrib (IAM) S.A
PINK:MAOTF
|
$3.25 Billion |
|
Kingsemi Co Ltd
SHG:688037
|
$3.25 Billion |
|
Sandstorm Gold Ltd N
NYSE:SAND
|
$3.25 Billion |
|
Guangzhou Great Power Energy&Technology Co Ltd
SHE:300438
|
$3.25 Billion |
|
Centerra Gold Inc
NYSE:CGAU
|
$3.25 Billion |
|
Legend Biotech Corp
NASDAQ:LEGN
|
$3.25 Billion |
|
Tegna Inc
NYSE:TGNA
|
$3.24 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hansoh Pharmaceutical Group Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,794,773,000 to 28,679,914,000, a change of 2,885,141,000 (11.2%).
- Net income of 4,371,825,000 contributed positively to equity growth.
- Dividend payments of 1,858,348,000 reduced retained earnings.
- Other factors increased equity by 372,171,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.37 Billion | +15.24% |
| Dividends Paid | $1.86 Billion | -6.48% |
| Other Changes | $372.17 Million | +1.3% |
| Total Change | $- | 11.18% |
Book Value vs Market Value Analysis
This analysis compares Hansoh Pharmaceutical Group Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.89x to 0.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $3.02 | $2.69 | x |
| 2021-12-31 | $3.38 | $2.69 | x |
| 2022-12-31 | $3.83 | $2.69 | x |
| 2023-12-31 | $4.35 | $2.69 | x |
| 2024-12-31 | $4.83 | $2.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hansoh Pharmaceutical Group Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.24%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 35.66%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.10x
- Recent ROE (15.24%) is above the historical average (13.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 14.37% | 29.56% | 0.42x | 1.16x | $781.35 Million |
| 2021 | 13.54% | 27.31% | 0.37x | 1.36x | $710.02 Million |
| 2022 | 11.41% | 27.54% | 0.31x | 1.32x | $319.05 Million |
| 2023 | 12.71% | 32.44% | 0.31x | 1.28x | $698.03 Million |
| 2024 | 15.24% | 35.66% | 0.39x | 1.10x | $1.50 Billion |
Industry Comparison
This section compares Hansoh Pharmaceutical Group Company Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,452,927
- Average return on equity (ROE) among peers: -31.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group Company Limited (HNSPF) | $31.10 Billion | 14.37% | 0.13x | $3.25 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $29.91 Million | 0.00% | 0.07x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |